Cargando…
Teaching an old dog new tricks: next-generation CAR T cells
Adoptive T cell therapy (ACT) refers to the therapeutic use of T cells. T cells genetically engineered to express chimeric antigen receptors (CAR) constitute the most clinically advanced form of ACT approved to date for the treatment of CD19-positive leukaemias and lymphomas. CARs are synthetic rece...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325111/ https://www.ncbi.nlm.nih.gov/pubmed/30413825 http://dx.doi.org/10.1038/s41416-018-0325-1 |
_version_ | 1783386077983145984 |
---|---|
author | Tokarew, Nicholas Ogonek, Justyna Endres, Stefan von Bergwelt-Baildon, Michael Kobold, Sebastian |
author_facet | Tokarew, Nicholas Ogonek, Justyna Endres, Stefan von Bergwelt-Baildon, Michael Kobold, Sebastian |
author_sort | Tokarew, Nicholas |
collection | PubMed |
description | Adoptive T cell therapy (ACT) refers to the therapeutic use of T cells. T cells genetically engineered to express chimeric antigen receptors (CAR) constitute the most clinically advanced form of ACT approved to date for the treatment of CD19-positive leukaemias and lymphomas. CARs are synthetic receptors that are able to confer antigen-binding and activating functions on T cells with the aim of therapeutically targeting cancer cells. Several factors are essential for CAR T cell therapy to be effective, such as recruitment, activation, expansion and persistence of bioengineered T cells at the tumour site. Despite the advances made in CAR T cell therapy, however, most tumour entities still escape immune detection and elimination. A number of strategies counteracting these problems will need to be addressed in order to render T cell therapy effective in more situations than currently possible. Non-haematological tumours are also the subject of active investigation, but ACT has so far shown only marginal success rates in these cases. New approaches are needed to enhance the ability of ACT to target solid tumours without increasing toxicity, by improving recognition, infiltration, and persistence within tumours, as well as an enhanced resistance to the suppressive tumour microenvironment. |
format | Online Article Text |
id | pubmed-6325111 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-63251112019-11-09 Teaching an old dog new tricks: next-generation CAR T cells Tokarew, Nicholas Ogonek, Justyna Endres, Stefan von Bergwelt-Baildon, Michael Kobold, Sebastian Br J Cancer Review Article Adoptive T cell therapy (ACT) refers to the therapeutic use of T cells. T cells genetically engineered to express chimeric antigen receptors (CAR) constitute the most clinically advanced form of ACT approved to date for the treatment of CD19-positive leukaemias and lymphomas. CARs are synthetic receptors that are able to confer antigen-binding and activating functions on T cells with the aim of therapeutically targeting cancer cells. Several factors are essential for CAR T cell therapy to be effective, such as recruitment, activation, expansion and persistence of bioengineered T cells at the tumour site. Despite the advances made in CAR T cell therapy, however, most tumour entities still escape immune detection and elimination. A number of strategies counteracting these problems will need to be addressed in order to render T cell therapy effective in more situations than currently possible. Non-haematological tumours are also the subject of active investigation, but ACT has so far shown only marginal success rates in these cases. New approaches are needed to enhance the ability of ACT to target solid tumours without increasing toxicity, by improving recognition, infiltration, and persistence within tumours, as well as an enhanced resistance to the suppressive tumour microenvironment. Nature Publishing Group UK 2018-11-09 2019-01-08 /pmc/articles/PMC6325111/ /pubmed/30413825 http://dx.doi.org/10.1038/s41416-018-0325-1 Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Review Article Tokarew, Nicholas Ogonek, Justyna Endres, Stefan von Bergwelt-Baildon, Michael Kobold, Sebastian Teaching an old dog new tricks: next-generation CAR T cells |
title | Teaching an old dog new tricks: next-generation CAR T cells |
title_full | Teaching an old dog new tricks: next-generation CAR T cells |
title_fullStr | Teaching an old dog new tricks: next-generation CAR T cells |
title_full_unstemmed | Teaching an old dog new tricks: next-generation CAR T cells |
title_short | Teaching an old dog new tricks: next-generation CAR T cells |
title_sort | teaching an old dog new tricks: next-generation car t cells |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325111/ https://www.ncbi.nlm.nih.gov/pubmed/30413825 http://dx.doi.org/10.1038/s41416-018-0325-1 |
work_keys_str_mv | AT tokarewnicholas teachinganolddognewtricksnextgenerationcartcells AT ogonekjustyna teachinganolddognewtricksnextgenerationcartcells AT endresstefan teachinganolddognewtricksnextgenerationcartcells AT vonbergweltbaildonmichael teachinganolddognewtricksnextgenerationcartcells AT koboldsebastian teachinganolddognewtricksnextgenerationcartcells |